Lineage Cell Therapeutics

LCTX · NYSE American

$0.9726+$0.0198 (+2.08%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $0.9528

LCTX analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $5.61 (+476.8% upside)

Low: $3.03
Now: $0.9726
High: $9.45

Upgrades and downgrades

The latest rating actions, newest first

LCTX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Jul 14, 2026	Maintains	Buy	$9.00	40%
D. Boral Capital	May 4, 2026	Maintains	Buy	$3.00	29%
Canaccord Genuity	Apr 28, 2026	Initiates	Buy	$9.00	35%
B. Riley Securities	Mar 25, 2026	Maintains	Buy	$3.00 → $4.00	47%
HC Wainwright & Co.	Mar 24, 2026	Maintains	Buy	$9.00	40%
D. Boral Capital	Mar 6, 2026	Maintains	Buy	$2.00 → $3.00	29%
D. Boral Capital	Feb 9, 2026	Maintains	Buy	$2.00	29%
D. Boral Capital	Nov 25, 2025	Maintains	Buy	$2.00	29%
HC Wainwright & Co.	Nov 24, 2025	Maintains	Buy	$9.00	40%

The case for and against

Updated Oct 21, 2026

Bull case

Lineage Cell Therapeutics is well positioned because it is methodically leveraging its proprietary AlloSCOPE platform and manufacturing expertise to advance off-the-shelf cell therapies that can be produced consistently at scale, a key advantage for commercialization and margin potential. COR1’s rapid preclinical progress, along with its strategy to address the cost and supply limitations of cadaver-derived corneal endothelial cells, supports a differentiated value proposition in ophthalmology. The bullish case is further strengthened by OpRegen’s durable 36-month Phase 1/2a data, including +6.2 letters in mean BCVA and +9.0 letters in the high-coverage subgroup, plus the Roche and Genentech partnership that adds external validation.

Bear case

Lineage Cell Therapeutics is exposed to substantial fundamental risk because its valuation depends heavily on two clinical programs, with OpRegen contributing 91% and OPC1 9%, leaving the story highly concentrated and vulnerable to setbacks. The company is still tied to regenerative medicine, a field that has progressed more slowly than expected and has yet to deliver a clear pivotal or commercial win, so failed or inconclusive trials could quickly undermine confidence. In addition, the need to secure adequate funding, along with clinical, regulatory, partnership, commercial, legal, and intellectual property risks, creates a fragile outlook despite exposure to dry AMD, which represents 80-90% of the AMD market.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.